Study wrapper · #937
Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.
Zhang Y, Zhang C, Gong X, et al. European journal of medical research. 2026.
DOI: 10.1186/s40001-026-03933-9PubMed: 41582189
Editor's note
This network meta-analysis pools twelve randomized trials and reports a consistent heart-rate increase across the GLP-1 agonist class. The signal is a well-documented pharmacological effect rather than a new finding, and the analysis is limited by heterogeneity across the included trials. Useful context for the cardiovascular profile of these agents.
Plain-language abstract
A meta-analysis of randomized trials found that GLP-1 receptor agonists, including semaglutide, tirzepatide, and retatrutide, were associated with modest increases in resting heart rate in people with overweight or obesity who did not have diabetes.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026